Journal
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
Volume 31, Issue 3, Pages 468-476Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/08923970902795203
Keywords
Mucin4; peptide; dendritic cell; cytotoxic T lymphocyte; vaccine
Categories
Funding
- National Nature Science Foundation of China [30500492, 30471691]
Ask authors/readers for more resources
Recent research has indicated that MUC4 plays an important role in the development of many tumors and may prove useful as a novel cancer immunotherapy target. We aimed to identify HLA-A*0201-restrictive cytotoxic T lymphocyte (CTL) epitopes of the cancer-associated antigen MUC4. The MUC4 sequence was scanned for immunogenic peptides using HLA-binding prediction software. Dendritic cells (DCs) from peripheral blood mononuclear cells (PBMCs) were induced by cytokines. Five possible CTL epitopes were selected by software analysis, synthesized, and used to pulse mature DCs. The CD8(+)Tcells from PBMCs from an HLA-A*0201 healthy donor were stimulated with autologous MUC4-peptide-loaded DCs and expanded in vitro. T cell activation was assessed by ELISPOT, and cytotoxicity was determined by (51)chromium (Cr-51)release assays. Our results show that CTLs induced by peptide P01204 could lyse T2 cells pulsed with peptide P01204 and HCT-116 cells (MUC4(+), HLA-A2(+)). Compared with a control peptide, P01204 increased the number of IFN-gamma producing T cells. Overall, these results suggest that P01204 is a novel HLA-A*0201 restrictive CTL epitope of the cancer-associated antigen MUC4. This will provide a foundation for the development of tumor-specific peptide vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available